There are currently 196 active clinical trials seeking participants for Multiple Myeloma research studies. The states with the highest number of trials for Multiple Myeloma participants are California, New York, Ohio and Texas.
The Ambient Light Multiple Myeloma Study
NCT05737732
Recruiting
The aim of this multi-site randomized control trial will be is to assess the impact Systematic lighting on circadian rhythm entrainment, Inflammation, Neutropenic Fever and Symptom Burden among Multiple Myeloma Patients undergoing Autologous Stem Cell Transplantation. To achieve this aim, 200 multiple myeloma patients will receive one of two different light-treatments that are designed to promote circadian rhythm alignment. While receiving these light treatments, participants' sleep efficiency,... Read More
Gender:
All
Ages:
21 years and above
Trial Updated:
06/06/2024
Locations: Icahn Schoool of Medicine at Mount Sinai, New York, New York +1 locations
Conditions: Multiple Myeloma
Register for Updates
MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT05020236
Recruiting
The purpose of this study is to evaluate whether the BCMA-CD3 bispecific antibody elranatamab, alone and/or in combination with the anti-CD38 monoclonal antibody, daratumumab, can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone. People with multiple myeloma who have received previous treatment including lenalidomide and a proteasome inhibitor will be enrolled in the study. Part 1 of the study will asses... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: Clovis Community Medical Center, Clovis, California +259 locations
Conditions: Multiple Myeloma
Register for Updates
High Dose Ascorbic Acid for Plasma Cell Disorders
NCT03602235
Recruiting
This is a Phase I single-arm open-label clinical study primarily assessing the safety and secondarily, the relative efficacy of low dose melphalan + high dose ascorbate acid (HDAA) in relapsed refractory patients with multiple myeloma.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/05/2024
Locations: University of Iowa Hospitals and Clinics, Iowa City, Iowa
Conditions: Multiple Myeloma
Register for Updates
18F-Fluciclovine PET/CT in Multiple Myeloma
NCT06103838
Recruiting
Background: Multiple myeloma (MM) is an incurable cancer of certain blood cells. MM often returns after treatment, and most people survive only 5 to 8 years after diagnosis. To improve survival, researchers need to find ways to identify returning disease earlier. Objective: To find out if the radiotracer 18F-fluciclovine (a substance injected into the blood during imaging scans) is better at detecting MM than the one (18F-FDG) currently used for this purpose. Eligibility: Adults aged 18 yea... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
06/04/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Relapsed and/or Refractory Multiple Myeloma (RRMM)
Register for Updates
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
NCT03412877
Recruiting
Background: A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are studied to find the parts that make the attack possible. White blood cells are then taken from the person s body, and the gene transfer occurs in a laboratory. A type of virus is used to transfer the genes that make those white blood cells able to attack the mutation in the tumor. The gene transfer therapy is the return of those white blood... Read More
Gender:
All
Ages:
Between 18 years and 72 years
Trial Updated:
06/04/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Endocrine Tumors, Neuroendocrine Tumors, Gastrointestinal/Genitourinary Cancers, Multiple Myeloma
Register for Updates
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
NCT06106945
Recruiting
This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD0305 in participants with RRMM.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: Research Site, Duarte, California +25 locations
Conditions: Multiple Myeloma
Register for Updates
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
NCT05257083
Recruiting
The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple myeloma patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: University of Arkansas, Little Rock, Arkansas +125 locations
Conditions: Multiple Myeloma
Register for Updates
Outpatient Administration of Teclistamab for Multiple Myeloma
NCT05972135
Recruiting
This is a phase II study to evaluate the Outpatient Administration of Teclistamab in Multiple Myeloma Patients
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Colorado Blood Cancer Institute, Denver, Colorado +4 locations
Conditions: Multiple Myeloma
Register for Updates
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
NCT04653246
Recruiting
This research is testing whether the investigational drug isatuximab is safe and effective when used in combination with standard agents for the treatment of newly diagnosed multiple myeloma.
Gender:
All
Ages:
75 years and above
Trial Updated:
05/31/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant
Register for Updates
Financial Difficulty in Patients With Blood Cancer
NCT05212233
Recruiting
This is a hypothesis-driven, observational, cross-sectional, multi-site study of the financial difficulties experienced by patients undergoing treatment for multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). It is composed of a patient survey (n=250) (Appendix A), a physician survey (n=100) (Appendix B), and a practice survey completed by each site enrolling patients onto this study (Appendix C). A subset of enrolled patients (n=35) will be invited to participate in an optional second... Read More
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
05/31/2024
Locations: Mayo Clinic Cancer Center, Phoenix, Arizona +2 locations
Conditions: Chronic Lymphocytic Leukemia, Multiple Myeloma
Register for Updates
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
NCT06215118
Recruiting
The main purpose of the study is to understand how safe and tolerable is elranatamab when given along with iberdomide. There are 2 parts to this study. Part 1 will look at how safe and tolerable is elranatamab when given with iberdomide. Part 2 will look at the correct amount of this combination that can be given to patients with relapsed or refractory multiple myeloma. Myeloma is a type of cancer that begins in plasma cells (white blood cells that produce antibodies). Refractory means a disea... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: MSK Basking Ridge, Basking Ridge, New Jersey +9 locations
Conditions: Multiple Myeloma
Register for Updates
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
NCT05776979
Recruiting
To learn if isatuximab can help to control highrisk MM when given in combination with lenalidomide after an autologous stem cell transplantation (ASCT).
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
05/28/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Multiple Myeloma
Register for Updates